PYXS

Pyxis Oncology Inc

1.84

Oct 20 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: STRO BCYC BCAX ZYME ADCT PDSB IPHA ALXO CHRS CUE

| Held by: VTI VXF IBB IWC BUSM IBBQ BIB

Index	-
Market Cap	220.03M
Enterprise Value	203.39M
Income	-88.73M
Sales	11.04M
Book/sh	0.18
Cash/sh	0.29
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	56
IPO	Oct 08, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	19.93
P/B	10.20
P/C	6.38
P/FCF	-
EV/EBITDA	-
EV/Sales	18.42
Quick Ratio	1.34
Current Ratio	1.34
Debt/Eq	1.56
LT Debt/Eq	1.40
Option/Short	Yes / Yes

EPS (ttm)	-1.40
EPS next Y	-1.11
EPS next Q	-0.28
EPS this Y	5.21%
EPS next Y	8.70%
EPS next 5Y	6.15%
EPS past 3/5Y	29.49% -27.93%
Sales past 3/5Y	- -
EPS Y/Y TTM	11.70%
Sales Y/Y TTM	291.42%
EPS Q/Q	-33.64%
Sales Q/Q	-100.00%
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-14.29% -100.00%

Insider Own	13.92%
Insider Trans	0.00%
Inst Own	32.87%
Inst Trans	0.28%
ROA	-99.62%
ROE	-179.10%
ROIC	-323.25%
Gross Margin	40.46%
Oper. Margin	-834.44%
Profit Margin	-803.83%
SMA20	-17.27%
SMA50	-35.67%
SMA200	-14.48%
Trades

Shs Outstand	119.58M
Shs Float	102.94M
Short Float	4.75%
Short Ratio	3.81
Short Interest	4.89M
52W High	5.55 -66.85%
52W Low	1.03 78.64%
Volatility	7.60% 7.43%
ATR (14)	0.20
RSI (14)	32.29
Beta	1.38
Rel Volume	0.00
Avg Volume	1.28M
Volume	0

Perf Week	-0.54%
Perf Month	-42.32%
Perf Quarter	-27.27%
Perf Half Y	7.60%
Perf YTD	60.00%
Perf Year	-48.60%
Perf 3Y	12.20%
Perf 5Y	-85.29%
Perf 10Y	-
Recom	1.20
Target Price	8.67
Prev Close	1.84
Price	1.84
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-03-26	Initiated	Wells Fargo	Overweight	$12
May-05-26	Initiated	Wedbush	Outperform	$6
Nov-03-25	Resumed	Stifel	Buy	$9
Sep-04-25	Initiated	Guggenheim	Buy	$5
Nov-21-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-08-24	Initiated	Stephens	Overweight	$13
Aug-08-24	Initiated	Stifel	Buy	$10
May-07-24	Resumed	Jefferies	Buy	$10
Feb-09-24	Initiated	BTIG Research	Buy	$8
Jan-23-24	Initiated	Leerink Partners	Outperform	$12
Sep-05-23	Initiated	RBC Capital Mkts	Outperform	$7
Nov-02-21	Initiated	Jefferies	Buy	$25
Nov-02-21	Initiated	Credit Suisse	Outperform	$19
Nov-02-21	Initiated	BofA Securities	Neutral	$16

Show Previous Ratings

Oct-02-26 07:00AM	Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering (GlobeNewswire)
Sep-30-26 01:11AM	Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering (GlobeNewswire) -19.66%
Sep-29-26 05:19PM	Pyxis Oncology stock falls on public offering announcement (Investing.com)
04:24PM	Pyxis Oncology Announces Proposed Public Offering (GlobeNewswire)
Sep-09-26 10:08AM	Pyxis Oncology shares fall 7% despite updated MICVO trial results (InvestorsHub) -13.11%
07:00AM	Loading…
07:00AM	Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) (GlobeNewswire)
Sep-08-26 04:01PM	Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) (GlobeNewswire)
07:30AM	Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board (GlobeNewswire)
Sep-01-26 07:30AM	Pyxis Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.17%
Aug-13-26 07:00AM	Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones (GlobeNewswire) -5.35%
Jun-30-26 07:30AM	Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones (GlobeNewswire) +5.24%
May-14-26 07:00AM	Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones (GlobeNewswire) -15.65%
May-13-26 07:30AM	Pyxis Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-07-26 04:05PM	Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer (GlobeNewswire) +21.24%
May-06-26 08:35AM	NanoViricides Measles Treatment Granted Orphan Drug Designation by FDA (Exec Edge) +25.68%
04:05PM	Loading…
Apr-17-26 04:05PM	Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 (GlobeNewswire)
Mar-23-26 07:00AM	Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-03-26 06:45AM	Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity (GlobeNewswire)
Dec-18-25 07:00AM	Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire) -48.66%
Nov-03-25 04:05PM	Pyxis Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.02%
07:00AM	Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-15-25 06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks) +13.31%
Oct-14-25 12:00PM	Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -6.38%
10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
Oct-13-25 04:05PM	Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings (GlobeNewswire) -6.76%
Oct-09-25 07:30AM	Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets (GlobeNewswire) +31.62%
Sep-30-25 04:24PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-15-25 09:55AM	Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross? (Zacks)
Sep-08-25 09:42AM	Investing in Oncology: 3 Cancer Stocks With Promising Pipelines (Zacks)
Aug-21-25 07:30AM	Pyxis Oncology to Participate in September Investor and Industry Conferences (GlobeNewswire) +13.79%
04:05PM	Loading…
Aug-14-25 04:05PM	Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +5.61% +8.85%
Jun-30-25 04:30PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-25 07:00AM	Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-14-25 07:30AM	Pyxis Oncology to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -10.08%
Apr-25-25 01:17PM	Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC (GlobeNewswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks) +5.88%
Apr-16-25 09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-02-25 07:30AM	Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) +11.48%
Mar-25-25 04:30PM	Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 (GlobeNewswire) -8.70%
Mar-18-25 07:30AM	Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -8.62%
Mar-03-25 07:30AM	Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -6.72%
Feb-26-25 07:30AM	Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer (GlobeNewswire) -5.83%
Feb-04-25 07:30AM	Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial (GlobeNewswire)
Dec-21-24 07:40AM	Pyxis Oncology price target lowered to $8 from $10 at RBC Capital (TipRanks)
Dec-19-24 04:08PM	Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 (GlobeNewswire) +9.74%
Nov-20-24 04:05PM	Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data (GlobeNewswire) -8.17% -45.03%
Nov-12-24 07:30AM	Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 (GlobeNewswire)
Nov-11-24 07:00AM	Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 (GlobeNewswire) +7.24%
Aug-29-24 07:30AM	Pyxis Oncology to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 04:05PM	Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024 (GlobeNewswire)
Jul-29-24 08:00AM	Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-28-24 04:30PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-10-24 07:30AM	Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger (GlobeNewswire)
May-30-24 07:30AM	Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 03:53PM	PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:40AM	Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024 (GlobeNewswire)
May-09-24 07:30AM	Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.62%
Apr-12-24 09:55AM	Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect? (Zacks) -6.64%
Mar-28-24 04:30PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.44%
Mar-27-24 07:30AM	Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights (GlobeNewswire) +9.66%
Mar-26-24 12:00PM	All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy (Zacks)
Mar-21-24 01:53PM	PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023 (InvestorPlace) -8.66%
09:11AM	Pyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial Challenges (GuruFocus.com)
07:30AM	Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023 (GlobeNewswire)
Mar-13-24 08:00AM	Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA (GlobeNewswire) -6.14%
Mar-07-24 04:30PM	Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024 (GlobeNewswire) -9.63%
Mar-05-24 04:45PM	Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting (GlobeNewswire)
Feb-27-24 08:00AM	Pyxis Oncology Announces $50 Million Private Placement (GlobeNewswire) +33.26%
Dec-29-23 04:30PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +14.44%
Nov-28-23 07:00AM	Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer (GlobeNewswire)
Nov-07-23 04:30PM	Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Oct-23-23 11:27AM	Inspiring the Next Generation of Entrepreneurs at the Diversity and Equity Accelerator through Learning for Startups (DEALS) Workshop (PR Newswire)
Oct-13-23 09:00AM	New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review (PR Newswire)
Sep-27-23 09:18AM	Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 (GlobeNewswire)
Sep-14-23 05:03PM	Insider Sell: President and CEO Lara Sullivan Sells 27,917 Shares of Pyxis Oncology Inc (GuruFocus.com)
Aug-31-23 04:01PM	Pyxis Oncology to Participate in Two Upcoming Investment Conferences (GlobeNewswire) +6.42%
Aug-23-23 08:35AM	Pyxis Oncology Successfully Completes Acquisition of Apexigen (GlobeNewswire)
Aug-11-23 07:00AM	Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update (GlobeNewswire) +6.61%
Aug-01-23 04:01PM	Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-30-23 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-23 08:30AM	Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs (GlobeNewswire)
May-24-23 06:45AM	Pyxis Oncology to Acquire Apexigen (GlobeNewswire) -10.46%
May-11-23 07:00AM	Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Mar-31-23 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -33.17%
Mar-30-23 02:16PM	Pyxis Stock Is Up 170% This Week. How Much Higher Can It Go? (TipRanks) +32.16%
Mar-22-23 06:45AM	Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update (GlobeNewswire)
Mar-16-23 07:30AM	Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors (GlobeNewswire) +7.46%
Feb-13-23 08:00AM	Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference (GlobeNewswire)
Dec-23-22 04:45PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79%
Dec-01-22 06:45AM	Pyxis Oncology Announces FDA Clearance of Two IND Applications (GlobeNewswire)
Nov-01-22 06:30AM	Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update (GlobeNewswire) -9.63%
Sep-30-22 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-22 07:00AM	Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update (GlobeNewswire)
Jul-12-22 06:45AM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-28-22 06:35AM	Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference (GlobeNewswire)
Jun-21-22 10:40AM	Great news for Pyxis Oncology, Inc. (NASDAQ:PYXS): Insiders acquired stock in large numbers last year (Simply Wall St.)
May-19-22 06:35AM	Pyxis Oncology Announces Presentations at Upcoming Investor Conferences (GlobeNewswire)
May-13-22 08:03AM	Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update (GlobeNewswire) -9.01%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dupont Jakob	Director	Jun 30 '26	Proposed Sale	3.06	35,000	107,034		Jun 30 04:13 PM

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

CEO & ChairmanMr. Thomas Civik

CPAMr. Jitendra Wadhane C.A.

Interim Chief Technology OfficerDr. Balu N. Balasubramanian Ph.D.

Head of Human ResourcesDonna Regalado

Senior Vice President of Portfolio & Program ManagementDr. Charles T. Gombar Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PYXS

Pyxis Oncology Inc

Upgrade your Finviz experience